शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEPhaarmasia Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 11 Aug, 2025 · 17:03 IST

Financial Results for the Quarter ended

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.8%Reaction day
₹27.50
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.0%+1.8% vs market
Pharmaceuticals peers, median of 151sector+0.0%+1.8% vs sector

On the reaction day the stock moved 1.8 pts more than Nifty Microcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.8+0.0+1.8+0.0+1.8
Next day
-2.5+0.7-3.2+0.1-2.6
2d
-4.0-0.1-3.9-0.1-3.9
3d
+0.8+1.4-0.6+0.2+0.6
4d
+5.8+2.6+3.2+0.3+5.5
5d
+3.3+2.5+0.8+0.4+2.9
1w
+10.5+2.2+8.3+0.9+9.6
15d
+23.6+1.9+21.7-0.5+24.2
1m
+34.1+2.8+31.3+1.7+32.4
2m
+9.1+1.2+7.9-1.7+10.9
3m
+23.6+2.2+21.4-3.3+26.9
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Phaarmasia Ltd reported its Q1 FY26 results on 11 August 2025. Revenue from operations stood at Rs. 687.36 lakhs, down from Rs. 829.19 lakhs in the same quarter last year, marking a year-on-year decline of about 17%. Total income came in at Rs. 718.88 lakhs versus Rs. 843.94 lakhs YoY. Net profit for the quarter was Rs. 27.02 lakhs, marginally lower than Rs. 27.64 lakhs in Q1 FY25, with basic EPS of Rs. 0.40. The statutory auditor, Sathuluri & Co, issued an unmodified opinion on the limited review of these results, confirming no material misstatements. The company continues to operate as a single-segment entity.

Likely market impact

The year-on-year drop in revenue is a concern, though the company managed to maintain profitability. With an unmodified audit opinion and stable single-segment operations, there are no immediate red flags, but shareholders should watch for a recovery in revenue trends in upcoming quarters.